English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
Dasatinib may be considered a new standard of care for pediatric patients with CML-CP
Dasatinib may be considered a new standard of care for pediatric patients with CML-CP
Madrid, June 2017 -Findings from a large prospective trial with pediatric patients1 suggest that dasatinib provides benefits to children and adolescents in CML-CP who are resistant /intolerant to imatinib.
CML represents less than 3% of all leukemias in children worldwide, but more aggressive disease characteristics have been observed in this patient population.
Currently imatinib is the only approved tyrosine kinase inhibitor in children with CML and no approved therapies are available for children resistant or intolerant to imatinib. "There is an unmet need for safe and effective treatment options for children and adolescents who are resistant or intolerant to imatinib and also for alternative treatment formulations", Dr C. Zwaan opened his presentation at the 22th meeting of the European Hematology Association (EHA) in Madrid.
According to Dr. Zwaan, dasatinib has already shown to be effective in adults with newly diagnosed CML-CP, as well as those resistant/intolerant to imatinib however, "there is almost no published data available in children who are resistant or intolerant to imatinib".
Zwaan presented data from a Phase II open-label, randomized, prospective study conducted in 18 countries. In this large, ongoing prospective trial of pediatric patients with CML-CP, dasatinib was found to be safe and effective as first, or second-line therapy.
Patients aged <18 years were recruited into three separate cohorts: (1) IM-resistant/intolerant CML-CP treated with dasatinib 60 mg/m2 QD, (2) IM-resistant/intolerant CML-AP/BP or Ph+ ALL, and (3) newly diagnosed CML-CP treated with dasatinib 60 mg/m2 or dasatinib 72 mg/m2 powder for oral suspension QD for ≥1 year. Within the imatinib resistant/intolerant group of 29 patients, 25 patients were resistant, 2 intolerant and 2 undetermined.
The primary objectives were MCyR for imatinib resistant/intolerant CML-CP at any time with more than 30% MCyR as the protocol-defined rate of clinical interest and CCyR for newly diagnosed CML-CP at any time with more than 55% CCyR as the protocol-defined rate of clinical interest.
The cumulative rate of MCyR >30% was reached as early as 3 months for IM-resistant/intolerant CML-CP, and a cumulative rate of CCyR >55% was reached as early as 6 months for newly diagnosed CML-CP. Cytogenetic and molecular response continued to increase over time in each cohort. "Early and durable responses to dasatinib were observed, which met the study objectives for both cohorts”, Zwaan summed up the efficacy study results.
The safety profile of dasatinib was comparable to previous reports in adults treated with dasatinib except that no cases of pleural/pericardial effusion or pulmonary arterial hypertension were observed.
Additional advantages include; once-daily dosing and administration with, or without food.
In conclusion, according to Zwaan, this is the largest prospective trial with pediatric patients and dasatinib was found to be a safe and effective treatment for pediatric patients in chronic-phase CML. The safety profile was slightly favourable to adult data with respect to the absence of effusions. “Further investigation is needed to determine whether the reasons for this slightly better safety profile in pediatric patients are due to a better immune system or any other reason”, Zwaan concluded at the end of his presentation.
1. Dasatinib in children and adolescents with chronic myeloid leukemia in chronic phase (CML-CP) from a phase 2 trial, abstract presented by CM Zwaan during the 22nd Congress of the European Hematology Association (EHA), June 22-25, 2017 in Madrid, Spain.
Free abstract
{rscomments off}
CML Publications 2016
CML Publications 2016
| Clinical Publications | Scientific Publications |
| December 2016 | |
| Response to overexpresssion of ABCB1 as prediction marker for CML: How close we are to translation into clinics? (Eadie LN et al. Leukemia, December 2016) (epub ahead of print) |
CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukemia patients (Barrat DT et al. Clin Pharmacokinet, December 2016) (epub ahead of print) |
| Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukemia (Constance C. et al. Leukemia, December 2016) (epub ahead of print) |
RT-q PCR and RT-Digital PCR: A comparison of different platforms for the evaluation of residual diseease in chronic myeloid leukemia Alikian M et al. Clin Chem, December 2016 (epub ahead of print) |
|
Chronic myeloid leukemia: sequencing of TKI therapies |
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study (Rousselot P et al. Cancer, December 2016) (epub ahead of print) |
|
Molecular monitoring in chronic myeloid leukemia - how low can you go? |
Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients (Arun AK et al. Int J Lab Hematol, December 2016) (epub ahead of print) |
| Long-term bosutinib for chronic phase myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib (Cortes JE et al. Am J Hematol, December 2016) |
Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI (Agarwal P et al. Blood, December 2016) (epub ahead of print) |
| The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors (Efficace F et al. Hematology Am Soc Hematol Educ Program, December 2016) |
Response to overexpresssion of ABCB1 as prediction marker for CML: How close we are to translation into clinics? |
|
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia |
|
|
Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy |
|
| November 2016 | |
|
How can I treat atypical CML? |
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both BCR/Abl-dependent and BCR/Abl-independent mechanisms (Lan X et al. J Hematol Oncol, November 2016) |
| Second line small molecule therapy options for treating chronic myeloid leukemia (Molica M et al. Expert Opin Pharmacotherapy, November 2016) |
Cyclic AMO (cAMP) confers drug resistance against DNA damaging agents via PKAIA in CML cells (Xiao LY et al. Eur J Pharmacol, November 2016) (epub ahead of print) |
| Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients (Nishiwaki S. et al. Blood, November 2016) (epub ahead of print) |
Upreguating miR-146a by pyscion reverses multidrug resistance in human chronic myelogenous leukemia K562/ADM cells (Liu W et al. Am J Cancer Res, November 2016) |
| Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators (Ruiz MS et al. Leukemia, November 2016) |
Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia (Ben Batalla et al. Clin Cancer Res, November 2016) (epub ahead of print) |
| How can patient reported outcomes improve patient management in chronic myeloid leukemia? (De Marchi F. et al. Expert Rev Hematol, November 2016) (epub ahead of print) |
Different BCR/ABL protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction |
| Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: A systematic review and meta-analysis (Haguet H et al. Expert Opin Drug Saf, November 2016) (epub ahead of print) |
Casiopeina III-Ea, a copper-containing small molecule, inhibits the in viro growth of primitive hematopoietic cells from chronic myeloid leukemia |
| Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor (Uemura M et al. Int J Hematol, November 2016) (epub ahead of print) |
IncRNA UCA1 contributes to imatinib resistance by acting as a ceRNA against miR-16 in chronic myeloid leukemia cells (Xiao Y et al. DNA Cell Biol, November 2016) (epub ahead of print) |
|
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase
|
Gas6/AXL signaling regulates self-renewal of chronic myelogenous leukemia stem cells by stabilizing ß-catenin
|
| Celecoxib inhibits proliferation and survival of chronic myelogenous leukemia cells via AMPK-dependent regulation of ß-catenin and mTORC 1/2 (Riva B et al. Oncotarget, November 2016) (epub ahead of print) |
|
| Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenetic stimuli (Söderlund S. et al. Leuk Res, Nov, 2016) |
|
| The Rho-ROCK pathway is a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia (Basbous S et al. J Pathol, November 2016) |
|
| Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1 (35INS) (Berman E et al. Leuk Res, Oct 2016) |
|
| October 2016 | |
|
A population-based study of chronic myeloid leukemia patients treated with imatinib in first-line
|
PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia (Gupta P et al. Cancer Lett, October 2016) (epub ahead of print) |
| Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? (Rosti G. et al. Nat Rev Clin Oncol, October 2016) (epub ahead of print) |
CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression (Tarafdar A. et al. Blood, October 2016) (epub ahead of print) |
| Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship (Koller PB et al. Cancer, October 2016) (epub ahead of print) |
miRNAs in chronic myeloid leukemia: small molecules, essential function (Litwínska Z. et al. Leuk Lymphoma, October 2016) |
|
Current developments in molecular monitoring in chronic myeloid leukemia |
Programmed cell death 4 and BCR-ABL fusion gene expression are negatively correlated in chronic myeloid leukemia (Zhang X et al. Oncol Lett, Oct 2016) |
| September 2016 | |
|
Monitoring and defining early response: Where to draw the line? |
Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition (Scott MT et al. Cancer Discov, Sept 2016) (epub ahead of print) |
|
Discontinuation of TKI therapy and 'functional' cure for CML |
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells (Zhang B et al. Blood, Sept 2016) (epub ahead of print) |
| Management of CML blast crisis (Hehlmann R. et al. Best Pract Res Clin Haematol, September 2016) |
Constitutional t(8;22) (q24;q11.2) that mimics the variant Burkitt-type translocation in Philadelphia chromosomal positiv chronic myeloid leukemia |
| Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidates to ponatinib: an expert opinion (Breccia M et al. Ann Hematol, Sept 2016) (epub ahead of print) |
Micro RNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL mediated leukemogenesis (Choi J et al. Blood, Sept. 2016) (epub ahead of print) |
|
Dasatinib in imatinib-resistant or-intolerant chronic-phase chronic myeloid leukemia: 7-year follow-up of study CA180-034 |
Molecular monitoring of chronic myeloid leukemia: present and future
|
|
Ponatinib in the therapy of chronic myeloid leukemia |
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells (Carter BZ et al. Sci Transl Med, September 2016) |
| August 2016 | |
|
Long-term bosutinib for chronic phase myeloid leukemia after failure of imatinib plus dasatinib and/or bosutinib (epub ahead of print)
|
The BCR-ABL/NF-kB signal transduction network: a long lasting relationship in Philadelphia positiv leukemias
|
| Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome (Iurlo A et al. Oncotarget, August 2016) (epub ahead of print) |
Cepheid xpert monitor platform for the confirmation of BCR-ABL1 is conversion factors for the molecular monitoring of chronic myeloid leukemia |
| Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor (Uemura M et al. Int J Hematol, August 2016) (epub ahead of print) |
ABCB1 overexpression is a key inhibitor of resistance to tyrosine kinase inhibitors in CML cell lines (Eadie LN et al. PLoS one, August 2016) |
| In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. (Soverini S et al. BMC Cancer, August 2016) |
MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML (Liu YX et al. J Hematol Oncol, August 2016) |
| Multiparameter analysis of off-target effects of dasatinib on bone homeostasis in patients with newly diagnosed myelogenous leukemia (Hoehn D. et al. Clin Lymphoma Myeloma Leuk, Aug 2016) |
miR-101 sensitized K562 cell line to imatinib through JAK2 downregulation and inhibition of NF-kB target genes (Farhadi E et al. Tumour Biol, August 2016) (epub ahead of print) |
| A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase (Takahashi K et al. Cancer, Aug 2016) |
|
| When to consider allogeneic transplantation in CML (Radich J, Clin Lymphoma Myeloma Leuk, Aug 2016) |
|
| Imatinib intolerance is associated with blastic phase development in Philadelphia chromosome-positive chronic myeloid leukemia (Ángeles-Velázquez JL. Clin Lymphoma Myeloma Leuk, August 2016) |
|
| July 2016 | |
| Summary of the published Indian data on chronic myeloid leukemia (Singhal MK et al. South Asian J Cancer, Jul-Sept, 2016) |
A role for FOX01 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia (Wagle M et al. Leukemia, July 2016) |
| Pattern of chronic myeloid leukemia in the imatinib era in a sub-Saharan African setting (Faye BF et al. Ann Hematol, July 2016) (epub ahead of print) |
TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome (Weich N et al. Blood Celles Mol Dis, July 2016) |
|
A safety evaluation of omacetacine mepesuccinate for the treatment of chronic myeloid leukemia
|
Cooperation of imipramine and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia (Jorgensen KM et al. Oncotarget, July 2016) (epub ahead of print) |
| Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients (Dorer DJ et al. Leuk Res, July 2016) |
What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer? (Lewis M et al. Hematol Oncol, July 2016) (epub ahead of print) |
| Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia (Castagnetti F. et al. Haematologica, July 2016) (epub ahead of print) |
Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant points mutations in tyrosine kinases (Springuel L. et al. Cell Mol Life Sci, July 2016) (epub ahead of print) |
| Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies (Efficace F. et al. Support Care Cancer, July 2016) (epub ahead of print) |
Influence of CYP3A5*3 and ABCD1 C3435T on clinical outcomes and through plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia (Adeagbo BA et al. J Clin Pharm Ther, July 2016) (epub ahead of print) |
| Changes from imatinib mesylate to second generation tyrosine kinase inhibitors to improve renal impairment with imatinib mesylate in chronic myelogenous leukemia (Hino A et al. Int J Hematol, July 2016) (epub ahead of print) |
The clinical significance of ABCB1 overexpression in predicting outcome of patients undergoing first-line imatinib treatment (Eadie LN et al. Leukemia, July 2016) (epub ahead of print) |
| Advanced phase chronic myeloid leukemia in the TKI era - a report from the Swedish CML register (Söderlund S et al. Eur J Haematol, July 2016) (epub ahead of print) |
Measurement of BCR-ABL1 transcripts on the international scale in the United States: current status and best practices (Arora R et al. Leuk Lymphoma, July 2016) (epub ahead of print) |
| Pregnancy: part of life in chronic myelogenous leukemia (Law AD et al. Leuk Lymphoma, July 2016) (epub ahead of print) |
Impact of ABCD1 1236C> T-2677G> T-3435C> polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib
|
| Deep molecular reponses for treatment-free remission in chronic myeloid leukemia (Dulucq S et al. Cancer Med, July 2016) (epub ahead of print) |
The role for FOX01 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia (Wagle M et al. Leukemia, July 2016) |
| June 2016 | |
|
Incidence of second malignancies of chronic myelid leukemia during treatment with tyrosine kinase inhibitors |
Next-generation sequencing identifies major DNA methylation changes during progression of PH+ chronic myeloid leukemia |
| Discontinuing tyrosine kinase inhibitor therapy in chronic mylogenous leukemia: current understanding and future directions (Bhalla S. et al. Clin Lymphoma Myeloma Leuk, June 2016) (epub ahead of print) |
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the international scale |
|
Management of pregnant chronic myeloid leukemia patients |
A novel tubulin polymerization inhibitor, MPT0B206, downregulates BCR-ABL expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells |
|
'Real-life' study of imatinib therapy in chronic-phase myeloid leukemia: A novel retrospective observational longitudinal analysis |
Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for chronic myeloid leukemia (CML) |
| Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population (Bower H et al. J Clin Onol, June 2016) (epub ahead of print) |
Drug repurposing for chronic myeloid leukemia: in silicio and in vitro investigation of DrugBank database for allosteric BCR-ABL inhibitors (Singh VK et al. J Biomol Struct Dyn, June 2016) (epub ahead of print) |
| Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML study IV (Miranda et al. Leukemia, June 2016) |
A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia (Lyn X et al. Mol Cytogenet, June 2016) |
| Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: A population-based cohort study (Dahlén T et al. Ann Intern Med, June 2016) (epub ahead of print) |
MEF2C and CEBPA: Possible co-regulators in chronic myeloid leukemia disease progression (Agatheeswaran S. et al. Int J Biochem Cell Biol, June 2016) (epub ahead of print) |
|
Discontinuing tyrosine kinase inhibitor therapy in chronic mylogenous leukemia: current understanding and future directions |
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells |
|
Incidence of second malignancies of chronic myelid leukemia during treatment with tyrosine kinase inhibitors (Yin XF et al. Clin Lymphoma Myeloma Leuk, June 2016) (epub ahead of print) |
High IL-7-levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia |
|
European LeukemiaNet recommendations for the managment and avoidance of adverse events of treatment in chronic myeloid leukemia
|
Unleashing the guardian: the targetable BCR-ABL/HAUSP/PML/PTEN network in CML (Morotti A et al. Curr Drug Targets, June 2016) (epub ahead of print) |
| Next-generation sequencing identifies major DNA methylation changes during progression of PH+ chronic myeloid leukemia (Heller G et al. Leukemia, June 2016) |
|
| Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the international scale (Cross NC et al. Leukemia, June 2016) (epub ahead of print) |
|
| Drug repurposing for chronic myeloid leukemia: in silicio and in vitro investigation of DrugBank database for allosteric BCR-ABL inhibitors (Singh VK et al. J Biomol Struct Dyn, June 2016) (epub ahead of print) |
|
| A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia (Lyn X et al. Mol Cytogenet, June 2016) |
|
| A novel tubulin polymerization inhibitor, MPT0B206, downregulates BCR-ABL expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells (Chen CW et al. Apoptosis, June 2016) (epub ahed of print) |
|
| MEF2C and CEBPA: Possible co-regulators in chronic myeloid leukemia disease progression (Agatheeswaran S. et al. Int J Biochem Cell Biol, June 2016) (epub ahead of print) |
|
| Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for chronic myeloid leukemia (CML) (Liu F et al. Oncotarget, June 2016) (epub ahead of print) |
|
| May 2016 | |
|
Optimizing the use of TKI's in the management of chronic myelogenous leukemia |
Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an international scale |
|
Setting global standards for stem cell research and clinical translation: The 2016 ISSCR guidelines |
ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome positive cells |
|
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA 180-034 |
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase |
|
The treatment of CML at an environment with limited resources |
Next generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia |
| Final 5-year study results of DASASION: The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial (Cortes JE et al. J Clin Oncol, May 2016) (epub ahead of print) |
The rs61764370 functional variant in the KRAS oncogene is associated with chronic myeloid leukemia risk in women (Gutiérrez-Malacatt H. et al. Asian Pac J Cancer Prev, 2016) |
| Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis (Sasaki K et al. Haematologica, May 2016) (epub ahead of print) |
Effect of tyrosine kinase inhibitors of stemness in normal and chronic myeloid leukemia cells (Charaf L et al. Leukemia, May 2016) (epub ahead of print) |
| Management of advanced-phase chronic myelogenous leukemia (Radich JP. J Natl. Compr Canc Netw, May 2016) |
Comparison of branded and generics imatinib plasma concentrations in patients with chronic myelogenous leukemia - unicentric study (Ostojic A. et al. Clin Lymphoma Myeloma Leuk, May2016) |
|
Chronic myeloid leukemia reminiscences and dreams |
Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia (Irvine DA et al. Sci Rep, May2016) |
|
Safety and efficacy of the combination of pegylated interferon-alpha2b and dasatinib in newly diagnosed chronic phase chronic myeloid leukemia patients |
|
| Health-related quality of life outcomes in chronic myleloid leukemia patients treated with second generation tyrosine kinase inhibitors: Do we know enough? (Breccia M et al. Curr Med Res Opin, May 2016) |
|
| April 2016 | |
| Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial (Lipton JH et al. Lancet Oncol, April 2016) (epub ahead of print) |
Identification of CD25 as STAT5 dependent growth regulator of leukemic stem cells in PH+ CML |
| Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China (Jiang Q et al. J Cancer Res Clin Oncol, April 2016) (epub ahead of print) |
Early BCR-ABL reduction is predictive of better event-free survival in patients with newly diagnosed chronic myeloid leukemia treated with any tyrosine kinase inhibitor |
| Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure (Whitely J et al. Curr Med Res Opin, April 2016) (epub ahead of print) |
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold based xenograft model |
| Monitoring disease burden in chronic myeloid leukemia: past, present, and future (Egan D. et al. Am J Hematol, April 2016) (epub ahead of print) |
Quantitative analysis of mutant subclones in chronic myeloid leukemia: comparison of different methodological approaches (Preuner S. et al. Int J Mol Sci, April) |
|
|
Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects Culen M et al. Oncotarget, April 2016 (epub ahead of print) |
|
|
Mtss1 is a critical epigenetically regulated tumor suppressor in CML |
|
The impact of multiple low-level BCR-ABL1 mutations on response to Ponatinib |
|
| Combined population dynamics and entropy modelling supports patients stratification in chronic myeloid leukemia (Brehme M et al. Sci Rep, April 2016) |
|
| March 2016 | |
| Cross-intolerance with dasatinib among imatinib-intolerant patients with chronic phase myeloid leukemia
(Khoury HJ et al. Clin Lymphoma Myeloma Leuk, March 2016) |
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy (Wang W et al. Blood, March 2016) (epub ahead of print) |
| Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phae chronic myelogenous leukemia patients (Fossard G. et al. Haematologica, March 2016) |
Leukemic stem cell quantification in newly diagnosed chronic myeloid leukamia patients predict response to nilotinib therapy (Thielen N et al. Clin Cancer Res, March 2016) (epub ahead of print) |
|
Increased prevalance of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia |
A role for FOXO1 in BCR-ABL-1 independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia |
| Next generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients (Soverini S. et al. Oncotarget, March 2016) (epub ahead of print) |
The role of Fas-associatd phosphotase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia (Huang W et al. Leukemia, March 2016) (epub ahead of print) |
|
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity |
Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway (Chen JR et al. Int. J Oncol, March 2016) (epub ahead of print) |
|
Long-term evaluation of cardiac and vascular toxicity in patients with philadelphia chromosome positive leukemias treated with Bosutinib |
Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance |
|
Splenic irradication before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study |
Micro RNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia |
|
Rotation of nilotinib and imatinib for first-line treatment of chronic myeloid leukemia |
Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3 (Wang H et al. Oncotarget, March 2016) (epub ahead of print) |
| Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States (Padula WV et al. J Natl Cancer Inst., March 2016) (epub ahead of print) |
NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells (Garcia-Alegría E et al. Cancer Lett, March 2016) (epub ahead of print) |
|
New methodologies in the molecular monitoring of CML |
c-MYB is a transcriptional regulator of ESPL1/separase in BCR-ABL-positive chronic myeloid leukemia (Prinzhorn W et al. Biomark Res, March 2016) (epub ahead of print) |
|
Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and/or renal dysfunction |
Next generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients |
| Present and future of molecular monitoring in chronic myloid leukaemia (Soverini S et al. Br J Haematol, March 2016) (epub ahead of print) |
Next generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients (Alikian M et al. J Mol Diagn, March 2016) |
| Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era? (Bansal A et al. Curr Opin Hematol, March 2016) (epub ahead of print) |
|
|
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial |
|
| February 2016 | |
| Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH study (Cortes JE et al. Clin Lymphoma Myeloma Leuk, February 2016) (epub ahead of print) |
High CIP2A levels correlates with an antiapoptoic phenotype that can be overcome by targeting BCL-XL in chronic meyloid leukemia (Lucas CM et al. Leukemia, February 2016) (epub ahead of print) |
| Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia (Caldemeyer L et al. Curr Hematol Malig Rep, February 2016) (epub ahead of print) |
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib resistance preventing rpS6 phosphorylation in chronic meyloid leukaemia cells: new combined therapeutic strategies |
| Hematologic malignancies in pregnancy: Management guidelines from an international consensus (Lishner M et al. J Clin Oncol, February 2016) |
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukemia (Latham S et al. J Clin Pathol, February 2016) (epub ahead of print) |
|
Quality of life and long-term therapy in patients with chronic myeloid leukemia |
Hsp90 inhibitor, BIIBo21, induces apoptosis and authopagy by regulating mTOR-UIIK1 pathway in imatinib-sensitive and-resistant chronic myeloid leukemic cells (He W et al. Int J Oncol, February 2016) |
|
Omacetaxine Mepesuccinate for chronic myeloid leukemia |
Normal ABL1 is a tumour suppressor and therapeutic target in human and mouse leukemias expressing oncogeneic ABL1 kinase (Dasgupta Y et al. Blood, February 2016) |
| Analysis of 2013 European LeukemiaNET (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcome (Jain P et al. Br. J Hematol, February 2016) |
Heterogeneity of leukemia-initiating capacity of chronic meylogenous leukemic stem cells (Zhang B et al. J Clin Invest, February 2016) (epub ahead of print) |
| Chronic Myeloid Leukemia: 2016 update on diagnosis, therapy and monitoring (Jabbour E et al. Am J Hematol, February 2016) |
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients (Deiniger MW et al. Blood, February 2015) |
| Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response and overall survival: A systemic review and meta-analysis (Douxfils J et al. JAMA Oncol, February 2016) (epub ahead of print) |
The role of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review (Di Stefano C et al. Oncol Rep, February 2016) |
| The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients (Kurtovic-Kozaric A et al. Br J Haematol, February 2016) (epub ahead of print) |
|
| Allogeneic transplantation for CML in the TKI era: striking the right balance (Innes AJ et al. Nat Rev Clin Oncol, February 2016) |
|
| January 2016 | |
| Conditional survival with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors (Sasaki K et al. Cancer, January 2016) |
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib (Parker WT et al. Blood, January 2016) (epub ahead of print) |
| Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France intergroup des leucémies myéloides chroniques (Rea D et al. Bull Cancer, January 2016) |
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia (Tanrikulu Simsek E et al. J Clin Pathol, January 2016) |
| Dasatinib first-line: Multicentric Italian experience outside clinical trials (Breccia M et al. Leuk Res, January 2016) |
Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors (epub ahead of print) |
| Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia (Pfirrmann M et al. Leukemia, January 2016) |
Identification and characterization of tyrosine kinase nonreceptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis |
| Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase myeloid leukaemia resistant or intolerant to imatinib (Brümmendorf TH et al. Br J Haematol, January 2016) (epub ahead of print) |
In silico identifcation of inhibitors against mutated BCR-ABL protein screening and molecular dynamics simultation study (Kumar H et al. J Biomol Struct Dyn, January 2016) (epub ahead of print) |
| Conditioned survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors (Sasaki K et al. Cancer, January 2015) |
|
| Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase (Akard LP et al. Leuk Lymphoma, January 2016) (epub ahead of print) |
|
Would you like to suggest an interesting paper or article? >> Please provide us with the details here and we will be happy to review your suggestion!
Search for more publications on CML at PubMed.gov
List of interesting CML Publications
List of interesting CML Publications
Please click here to find a selection of other recent clinical and scientific CML publications from peer-reviewed journals.
CML Publications 2016 |
|
| Clinical Publications | Scientific Publications |
| March 2016 | |
|
Splenic irradication before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study |
Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance (Patkar N et al. Leuk Lymphoma, March 2016) (epub ahead of print) |
| Rotation of nilotinib and imatinib for first-line treatment of chronic myeloid leukemia (Gugliotta G. Am J Hematol, March 2016) (epub ahead of print) |
Micro RNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia (Chakraborty C. et al. Oncotarget, March 2016) (epub ahead of print) |
|
Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States |
Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3 (Wang H et al. Oncotarget, March 2016) (epub ahead of print) |
|
New methodologies in the molecular monitoring of CML |
NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells |
| Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and/or renal dysfunction (Sasaki K et al. Clin Lymphoma Myeloma Leuk, March 2016) |
c-MYB is a transcriptional regulator of ESPL1/separase in BCR-ABL-positive chronic myeloid leukemia (Prinzhorn W et al. Biomark Res, March 2016) (epub ahead of print) |
| Present and future of molecular monitoring in chronic myloid leukaemia (Soverini S et al. Br J Haematol, March 2016) (epub ahead of print) |
Next generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients (Alikian M et al. J Mol Diagn, March 2016) |
| Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era? (Bansal A et al. Curr Opin Hematol, March 2016) (epub ahead of print) |
|
| February 2016 | |
| Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH study (Cortes JE et al. Clin Lymphoma Myeloma Leuk, February 2016) (epub ahead of print) |
High CIP2A levels correlates with an antiapoptoic phenotype that can be overcome by targeting BCL-XL in chronic meyloid leukemia (Lucas CM et al. Leukemia, February 2016) (epub ahead of print) |
| Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia (Caldemeyer L et al. Curr Hematol Malig Rep, February 2016) (epub ahead of print) |
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib resistance preventing rpS6 phosphorylation in chronic meyloid leukaemia cells: new combined therapeutic strategies |
| Hematologic malignancies in pregnancy: Management guidelines from an international consensus (Lishner M et al. J Clin Oncol, February 2016) |
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukemia (Latham S et al. J Clin Pathol, February 2016) (epub ahead of print) |
|
Quality of life and long-term therapy in patients with chronic myeloid leukemia |
Hsp90 inhibitor, BIIBo21, induces apoptosis and authopagy by regulating mTOR-UIIK1 pathway in imatinib-sensitive and-resistant chronic myeloid leukemic cells (He W et al. Int J Oncol, February 2016) |
|
Omacetaxine Mepesuccinate for chronic myeloid leukemia |
Normal ABL1 is a tumour suppressor and therapeutic target in human and mouse leukemias expressing oncogeneic ABL1 kinase (Dasgupta Y et al. Blood, February 2016) |
| Analysis of 2013 European LeukemiaNET (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcome (Jain P et al. Br. J Hematol, February 2016) |
Heterogeneity of leukemia-initiating capacity of chronic meylogenous leukemic stem cells (Zhang B et al. J Clin Invest, February 2016) (epub ahead of print) |
| Chronic Myeloid Leukemia: 2016 update on diagnosis, therapy and monitoring (Jabbour E et al. Am J Hematol, February 2016) |
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients (Deiniger MW et al. Blood, February 2015) |
| Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response and overall survival: A systemic review and meta-analysis (Douxfils J et al. JAMA Oncol, February 2016) (epub ahead of print) |
The role of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review (Di Stefano C et al. Oncol Rep, February 2016) |
| The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients (Kurtovic-Kozaric A et al. Br J Haematol, February 2016) (epub ahead of print) |
|
| Allogeneic transplantation for CML in the TKI era: striking the right balance (Innes AJ et al. Nat Rev Clin Oncol, February 2016) |
|
| January 2016 | |
| Conditional survival with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors (Sasaki K et al. Cancer, January 2016) |
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib (Parker WT et al. Blood, January 2016) (epub ahead of print) |
| Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France intergroup des leucémies myéloides chroniques (Rea D et al. Bull Cancer, January 2016) |
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia (Tanrikulu Simsek E et al. J Clin Pathol, January 2016) |
| Dasatinib first-line: Multicentric Italian experience outside clinical trials (Breccia M et al. Leuk Res, January 2016) |
Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors (epub ahead of print) |
| Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia (Pfirrmann M et al. Leukemia, January 2016) |
Identification and characterization of tyrosine kinase nonreceptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis |
| Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase myeloid leukaemia resistant or intolerant to imatinib (Brümmendorf TH et al. Br J Haematol, January 2016) (epub ahead of print) |
In silico identifcation of inhibitors against mutated BCR-ABL protein screening and molecular dynamics simultation study (Kumar H et al. J Biomol Struct Dyn, January 2016) (epub ahead of print) |
| Conditioned survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors (Sasaki K et al. Cancer, January 2015) |
|
| Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase (Akard LP et al. Leuk Lymphoma, January 2016) (epub ahead of print) |
|
CML Publications 2014/2015
Access 2015 CML publications here
Access 2014 CML publications here
Search for more publications on CML at PubMed.gov
CML Publications 2015
CML Publications 2015
| Clinical Publications | Scientific Publications |
| December 2015 | |
| MTSS1 is a critical epigenetically regulated tumor supressor in CML (Schemionek M et al. Leukemia, December 2015) (epub ahead of print) |
|
| Molecular monitoring in CML and the prospects for treatment-free remissions (Deininger MW. Hematology Am Soc Hematol Educ Program, December 2015) |
KIR2DL5D genotype predicts outcome in CML patients treated with response directed sequential imatinib/nilotinib strategy (Yeung et al. Blood, December 2015) |
| Is there a best TKI for chronic phase CML? (Larson RA. Hematology Am Soc Hematol Educ Program, December 2015) |
Impact of unbalanced minor route versus major route karyotypes at diagnosis and prognosis of CML (Fabarius A et al. Ann Hematol, December 2015) |
| Long-term BCR-ABL1 tyrosine kinase inhibitor therapy in chronic myeloid leukemia (Pinilla-Ibarz J et al. Anticancer Res, December 2015) |
Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR (Lund HL et al. Annal Bioannal Chem, December 2015) (epub ahead of print) |
| November 2015 | |
|
|
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients (Deiniger MW et al. Blood, November 2015) (epub ahead of print) |
|
|
Identification of CD25 as STAT5-dependent growth-regulator of leukemic stem cells in Ph+CML (Sadovnik I et al. Clin Cancer Res, November 2015) (epub ahead of print) |
|
The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia |
ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts (Valleta S et al. Oncotarget, November 2015) |
| Long-term outcomes after imatinib mesylate discontinuation in chronic myeloid leukaemia patients with undetectable minimal residual disease (Yhim HY et al. Acta Haematol, November 2015) (epub ahead of print) |
Association of promoter polymorphisms of Fas-FasL genes with development of chronic myeloid leukemia |
| October 2015 | |
| Expression of VEGF and it's effect on cell proliferation in patients with chronic myeloid leukemia (Chen H et al. Eur Rev Med Pharmacol Sci, October 2015) |
|
|
Incidence and management of myelosuppression in patients with chronic-and accelerated-phase chronic myeloid leukemia treated with oacetaxine mepesuccinate |
The BIM detection polymorphism: A paradigm of a permissive interaction germline and acquired TKI resistance factors in CML (Ko TK et al. Oncotarget, October 2015) (epub ahead of print) |
| Long-term outcome of patients with newly diagnosed chronic myeloid leukemia - A randomized comparison of stem cell transplantation with drug treatment (Gratwohl A et al. Leukemia, October 2015) (epub ahead of print) |
Discovery of survival factors for primitive chronic myeloid leukemia cells using induced pluripotent stem cells |
| Diagnosis and Treatment of chronic myeloid leukemia in 2015 (Mayo Clin Proc 2015, October, 2015) |
Accelerated phase chronic myeloid leukemia evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase |
| Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia (Kropf P et al. Leuk Lymphoma, October 2015) (epub ahead of print) |
Association of vascular endothelial growth factor A (VEGFA) and its receptor (VEGFR2) gene polymorphisms with risk of chronic myeloid leukemia and influence on clinical outcome |
| Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison (Firwana B et al. Int J Cancer, October 2015) (epub ahead of print) |
Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia |
| September 2015 | |
| Treatment outcomes in CML patients treated with tyrosine kinase inhibitors at a tertiary teaching hospital in South Africa (Sissolak G et al. Clin Lymphoma Leuk, September 2015) (epub ahead of print) |
|
| Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study (Jain P et al. Lancet Haematol, Sept. 2015) |
Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes ikBalpha mediated p53 nuclear exclusion |
|
Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program - Lessons learned from providing access to breakthrough targeted oncology treatment in low- and middle-income countries |
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcr-2 or Bcr Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells |
|
The impact of dasatinib on pregnancy outcomes |
Erosion of the chronic myeloid leukemia stem cell pool by PPARy agonists |
|
Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor (epub ahead of print) |
Implication of the autologous immune system in BCR-ABL transcript variations in chronic myelogneous leukemia patients treated with imatinib |
| Unique cutaneous reaction to second- and third-generation tyrosine kinase inhibitors for chronic myeloid leukemia (Patel AB et al. Dermatology, September 2015) (epub ahead of print) |
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia |
| August 2015 | |
|
|
ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cell and prolongs survial in murine model (Nasr RR et al. Int J Cancer, August 2015) |
|
|
Molecular response to imatinib and its correlation with mRNA expression levels of imatinib influx and efflux transporters in patients with chronic myeloid leukaemia in chronic phase (Malhotra H. et al. Indian J Med Res, August 2015) |
|
BCR-ABl mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact of survival |
Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in chronic myelogenous leukemia in era of tyrosine kinase inhibitors |
|
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib
|
miRNAs as Biomarkers in chronic myelogenous leukemia (Kotagama K et al. Drug Dev Res, August 2015) |
|
Comparison of Dasatinib, Nilotinib and Imatinib in the treatment of chronic myeloid leukemia |
Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold |
| July 2015 | |
|
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase myeloid leukemia. A patient-based survey on 1133 patients |
A longitudinal evaluation of performence of automated BCR-ABL1 quantification using cartridge-based detection system |
| Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome (Piekarska A. et al. Ann Hematol, July 2015) (epub ahead of print) |
MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia |
| Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors (Yilmaz M. et al. Cancer, July 2015) (epub ahead of print)
|
Tyrosine kinase inhibitor induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling |
| CML in pregnancy: A case report using leukapheresis and literatur review (Yellu M. et al. Transfus Apher Sci, July 2015) (epub ahead of print) |
ß-Catenin is required for intrinsic but not extrinsix BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia |
| Living with CML: is death no longer the end (point) (White DL. et al. Blood, July 2015) (epub ahead of print) |
A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits |
|
|
Sensitive replicate RT-qPCR of BCR-ABL show deep molecular response in long term post allogeneic SCT CML patients |
|
|
Detection of BCR-ABL T315I mutation by peptide nucleic directed PCR clamping and by peptide nucleic acid FISH |
|
|
BCR-ABL 1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR |
|
|
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia |
| June 2015 | |
| Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia (Gugliotta G.et al. Haematologica, June 2015) (epub ahead of print) |
Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats |
| Long-term efficacy and safety in patients with advanced leukemia following resistance/Intolerance to imatinib and other tyrosine kinase inhibitors (Gambacorti-Passerini C. et al. Am J Hematol, June 2015) (epub ahead of print) |
The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia |
|
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib |
Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia |
|
Expression of the ETS transcription factor GABPa is positively correlated to the BCR-ABL1 ration in CML patients and affects imatinib sensitivity in vitro |
|
|
|
Clonal evolution and blast crisis correlate with enhanced proteolytic activity of separase in BCR-ABL b3a2 Fusion Type CML under imatinib therapy |
|
|
Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia |
|
|
Reconsideration of BCR-ABL protein flow cytomatic immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia? |
|
Mai 2015 |
|
|
Treatment milestones in chronic myelogenous leukemia: Stay the course or change therapy?
|
CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia |
|
Diagnosing and managing advanced chronic myeloid leukemia |
1,3 butadiene, CML and the t(9:22) translocation: A reality check |
|
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response |
Dissecting the role of aberrant DNA methylation in human leukaemia |
|
Management of advanced-phase chronic myeloid leukemia |
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity |
|
Final analysis of the efficacy and safety of omacetacine mepesuccinate in patients with chronic- or accelerated phase chronic myloid leukemia: Results with 24 months of follow-up
|
Next generation deep sequencing improves detection of BCR-ABL 1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase (Machova Polakova K et al. J Cancer Res Clin Oncol, May 2015) |
|
April 2015 |
|
|
Cardiovascular and pulmonary adverse events in patients treated with BCR-AB inhibitors: Data from the FDA adverse event reporting system |
Milestones and Monitoring |
|
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML-Study IV |
Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis |
|
A phase I study of Danusertib (PHA 739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy |
Second allogeneic transplantation using unrelated cord blood for relapsed hematological malignancies after allogeneic transplantation |
| Managing pregnancy in chronic myeloid leukaemia (Palani R et al. Ann Hematol, April 2015) |
Coexpression of hyperactivated AKT1 with additional genes activated in leukemia drives hematopoietic progenitor cells to cell cycle block and apostosis |
|
A review of the European LeukemiaNet recommendations |
Detection of small abnormal b-lymphoblast populations at diagnosis of chronic myelogenous leukemia, BCR-ABL1+: incidence, phenotypic features, and clinical implications (Vrotsos E et al. Cytometry B Clin Cytom, April 2015) |
|
Discontinuation of tyrosine kinase inhibitor therapy in CML |
Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization |
|
Causes of resistance and treatment choices in second- and third-line treatment in chronic meylogenous leukemia patients |
Response related predictors of survival in CML |
|
The choice of first-line chronic myelogenous leukemia treatment |
BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts |
|
Chronic Myeloid Leukaemia |
Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase |
|
March 2015 |
|
|
Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: An evolving treatment paradigm (Jabbour et al. Clin Lymphoma Myeloma Leuk, March 2015) |
|
|
Update on emerging treatments for chronic myeloid leukemia |
Secondary mutations as mediators of resistance to targeted therapy in leukemias |
|
Second malignancies following treatment of chronic myeloid leukemia in the tyrosine kinase inhibitor era |
A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in CML (Bartley PA et al. J Mol Diagn, March 2015) |
|
Phase 3 study of nilotinib vs imatinib in chinese patients with newly diagnosed CML in chronic phase: ENESTchina |
|
|
February 2015 |
|
| TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependend molecular targets (Yeung DT et al. Blood, February 2015) |
Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid Leukemia: A meta-analysis of clinical trials of tyrosine kinase inhibitors |
|
Prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet2013 criteria |
Laboratory recommentations for scoring deep molecular responses following treatment for chronic myeloid leukemia
|
|
The role of observational studies in optimizing the clinical management of chronic myeloid leukemia |
Morgana acts as an oncosuppressor in chronic myeloid leukemia |
|
Generic imatinib in the treatment of chronic myeloid leukemia: The Carrahpasa experience |
Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid Leukemia: A meta-analysis of clinical trials of tyrosine kinase inhibitors |
|
|
Analyzing molecular response in chronic myleoid leukemia clinical trials: Pitfalls and golden rules |
| January 2015 | |
|
Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia |
Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia |
| Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors (Khoury HJ et al. Leuk Lymphoma, January, 2015) |
Antibody-based detection of protein phosphyorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines (Aspinall O'Dea et al. Nat Protoc, January 2015) |
|
Cardiovascular and pulmonary events in patients treated with BCR-ABL inhibitors: Data from the FDA adverse events reporting system |
BCR-ABL inactivates cytosolic PTEN through casein kinase II mediated tail phosphorylation |
|
Do we need more drugs for chronic myeloid leukemia? |
Patients with Philadelphina-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominately relapse with the same mutation |
|
Real-life comparison of severe vascular events and other non-hematological complications in chronic myeloid leukemia patients undergoing second line nilotinib or dasatinib treatment |
PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukemia patients in chronic phase |
|
ELN 2013 response status criteria: Relevance for a novo imatinib chronic phase myeloid leukemia patients? |
Disruption of IKAROS in primitive chronic phase CML mimics myeloid disease progression (Bear PA et al. Blood, January 2015) |
|
|
The BCR-ABL inhibitor ponatinib inhibits placelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. |
Would you like to suggest an interesting paper or article? >> Please provide us with the details here and we will be happy to review your suggestion!
Search for more publications on CML at PubMed.gov
Profie_Vasile Musteata
Vasile Musteata, MD, PhD, MPH
Associate Professor and vice-head for education
Department of Oncology, Hematology and Radiotherapy
“N. Testemitanu” State University of Medicine and Pharmacy
Chisinau, Moldova
Current professional position:
- Associate Professor and vice-head for education at the Department of Oncology, Hematology and Radiotherapy, “N. Testemitanu” State University of Medicine and Pharmacy
- Attending physician, division of Hematology, Institute of Oncology
- Clinical expert at the Agency of Medicine and Medical Devices
- GIPAP manager for Moldova
Fields of scientific activities:
- Diagnosis and treatment of malignant lymphomas and chronic leukemias
- Publications in peer-reviewed periodicals: 125 articles and abstracts (including 6 National Clinical Protocols), one invention
Postgraduate training and fellowships:
1. Postgraduate Medical Education Program in the speciality of Hematology, dept. of Hematology and Oncology, “N. Testemitanu” State University of Medicine and Pharmacy, Institute of Oncology; Chisinau, 1995 – 1997; MD degree
2. Internship on Hematology, Department of Hematology and Oncology, Krankenhaus Moabit; Berlin, Germany, 1 November – 30 December 1998
3. Salzburg – Cornell Seminars on Oncology/ Hematology under the auspices of Memorial Sloan-Kettering Cancer Center of New-York; Austria, 14 – 19 March 1999
4. International Scientific Conference Actual Problems of Clinical Hematology and Transfusion Medicine under the auspices of P.L. Shupyk Kyiv Medical Academy for Postgraduate Education; Ukraine, 1 – 3 June 1999
5. The AAF-OSI Medical Internship Program on Oncology and Hematology, Division of Hematology and Oncology, Innsbruck University Clinic; Austria, 30 September – 29 October 2000
6. Postgraduate Course on Hematology and Transfusion Medicine, dept. of Hematology and Oncology, “N. Testemitanu” State University of Medicine and Pharmacy, Institute of Oncology; Chisinau, 1997 – 2000; PhD degree
7. XXVII-ème Semaine Mèdicale Balkanique, L’Union Mèdicale Balkanique; Chisinau, Republic of Moldova, 19 – 21 June 2002
8. 27th European Society for Medical Oncology (ESMO) Congress; Nice, France, 18 – 22 October 2002
9. ESMO Summer Educational Conference; Edinburgh, Scotland, UK, 19 – 22 June 2003
10. Medical Internship Program on Internal Medicine / Hematology, Division of Internal Medicine and Hematology, King Abdullah University Hospital, Jordan University of Science and Technology; Irbid, Hashemite Kingdom of Jordan, 15 July – 8 August 2003
11. ESMO Postgraduate Course Principles and Practices in Medical Oncology, Maria Sklodowska-Curie Memorial Cancer Center; Warsaw, Poland, 4 – 6 September 2003
12. 29th ESMO Congress; Vienna, Austria, 29 October – 2 November 2004
13. ESMO Scientific and Educational Conference; Budapest, Hungary, 2 – 5 June 2005
14. Regional meeting of national managers – SEE Blood safety project under the auspices of WHO; Ljubljana, Slovenia, 17 – 18 June 2005
15. Salzburg – Cornell Seminars on Oncology under the auspices of Memorial Sloan-Kettering Cancer Center of New-York; Austria, 10 – 16 September 2006
16. 31th ESMO Congress; Istanbul, Turkey, 29 September – 3 October 2006
17. TEMPUS-TACIS „PROBMEDFORM” Project and CBCR-Seminars, L’Universita Cattolica del Sacro Cuore di Milano, Rome, Italy, 20 – 26 November 2006
18. Ukrainian School of Hematologists “Updated problems of treatment of hematological and viral diseases”; Kyiv, 19 – 20 June 2008
19. 33th ESMO Congress; Stockholm, Sweden, 12 – 16 September 2008
20. School of Public Health, N. Testemitanu” State University of Medicine and Pharmacy “; Chisinau, 2009 – 2011; MPH degree
21. Seminars “Perfections in Management of Public Health” under the auspices of Ecole de Santé Publique – Groupe Hospitalier Saint Augustin; France, 9 – 13 May 2011
22. Salzburg – Cornell Seminars on Oncology A: Hematologic Malignancies under the auspices of Memorial Sloan-Kettering Cancer Center of New-York; Austria, 22 – 28 April 2012
23. ERSAP Preceptorship Program in hematologic malignancies, Department of Leukemia, The University of Texas, MD Anderson Cancer Center; Houston, Texas, USA, 1 – 31 August 2012
24. 11th Annual Symposium of the European LeukemiaNet / 15th Annual Symposium of the German Competence Network “Acute and chronic Leukemias”; Mannheim, Germany, 4 – 5 February, 2014
